Success Metrics

Clinical Success Rate
70.0%

Based on 7 completed trials

Completion Rate
70%(7/10)
Active Trials
1(8%)
Results Posted
100%(7 trials)
Terminated
3(23%)

Phase Distribution

Ph phase_1
5
38%
Ph phase_2
3
23%
Ph phase_3
4
31%

Phase Distribution

5

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
5(41.7%)
Phase 2Efficacy & side effects
3(25.0%)
Phase 3Large-scale testing
4(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

63.6%

7 of 11 finished

Non-Completion Rate

36.4%

4 ended early

Currently Active

1

trials recruiting

Total Trials

13

all time

Status Distribution
Active(1)
Completed(7)
Terminated(4)
Other(1)

Detailed Status

Completed7
Terminated3
Withdrawn1
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
1
Success Rate
70.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (41.7%)
Phase 23 (25.0%)
Phase 34 (33.3%)

Trials by Status

withdrawn18%
active_not_recruiting18%
terminated323%
unknown18%
completed754%

Recent Activity

1 active trials
Showing 5 of 13
completedphase_3

Molecular Profiling of Advanced Soft-tissue Sarcomas

NCT03784014
completedphase_2

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

NCT03226418
active_not_recruitingphase_2

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

NCT04231851
terminatedphase_1

Glasdegib for Chronic Graft-Versus-Host Disease

NCT04111497
completedphase_3

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

NCT04842604
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT03784014Phase 3

Molecular Profiling of Advanced Soft-tissue Sarcomas

Completed
NCT03226418Phase 2

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

Completed
NCT04231851Phase 2

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Active Not Recruiting
NCT04111497Phase 1

Glasdegib for Chronic Graft-Versus-Host Disease

Terminated
NCT04842604Phase 3

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Completed
NCT03390296Phase 1

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Completed
NCT04230564

Acute Myeloid Leukemia Real World Treatment Patterns

Withdrawn
NCT03416179Phase 3

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

Completed
NCT04093505Phase 3

Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)

Terminated
NCT03415867Phase 1

Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease

Unknown
NCT04051996Phase 2

GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia

Terminated
NCT03130556Phase 1

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation

Completed
NCT02430545Phase 1

Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13